Kyorin Pharmaceutical Holdings Co., Ltd.

Greenhouse gas emissions & sustainability report data

📊 Latest report period: 2021-04 to 2022-03🗂️ Report periods on file: 2021-04 to 2022-03, 2020, 2019-04 to 2020-03, 2018-04 to 2019-03, 2018-04 to 2018-09, 2017-04 to 2018-03, 2016-04 to 2017-03, 2015-04 to 2016-03, 2014-04 to 2015-03, 2014, 2011

In its 2021-04 to 2022-03 reporting, Kyorin Pharmaceutical Holdings Co., Ltd. disclosed greenhouse gas emissions of 25.3K tCO2e/year. By scope: Scope 1: 13.2K tCO2e/year; Scope 2: 14.4K tCO2e/year; Scope 3: 18.0K tCO2e/year. Figures are as stated in the company's own report and may use different boundaries, units or methods (for example market-based vs location-based Scope 2), so compare with care.

💨
GHG Emissions
25.3K tCO2e/year
2021-04 to 2022-03
⚡
Renewable Energy
100% at headquarters (2021)
of total energy
💧
Water Usage
250.0K m3/year
2021-04 to 2022-03
♻️
Waste
724 tons/year
2021-04 to 2022-03
⚙️
Energy Use
494.7K GJ/year
2021-04 to 2022-03

📊 Emissions by Scope (2021-04 to 2022-03)

ScopeWhat it coversReported value
Scope 1Direct emissions from sources the company owns or controls (fuel combustion, company vehicles, process and fugitive emissions).13.2K tCO2e/year
Scope 2Indirect emissions from purchased electricity, steam, heat and cooling.14.4K tCO2e/year
Scope 3Other indirect emissions across the value chain (purchased goods, business travel, use of sold products, etc.).18.0K tCO2e/year

New to scopes? Read Scope 1, 2 and 3 emissions explained and market-based vs location-based Scope 2.

📈 Emissions by Report Period

Report periodHeadline emissions figure reported
2021-04 to 2022-0325.3K tCO2e/year
2019-04 to 2020-0327.5K tCO2e/year
2018-04 to 2019-0328.8K tCO2e/year
2017-04 to 2018-0317.0K tCO2e/year

Each row is the headline figure extracted from a different report; scope coverage and methodology can change between years.

✅ Reported Environmental Achievements

🎯 Climate & Sustainability Targets

🔜 Short-term

  • Reduce CO2 emissions by 1.5% annually until 2023.

📅 Medium-term

  • Achieve 15% women in management positions by 2030.

🌱 ESG Focus Areas

EnvironmentSocialGovernance

⚠️ Challenges & Risks +

  • Price revisions impacting profitability.
  • Supply chain disruptions due to quality issues in some generic drug companies.
  • Impact of the COVID-19 pandemic on market conditions.

📋 Report Information

Reporting Period: 2021-04 to 2022-03
Frameworks: IIRC International Framework